DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Summary for Patent: 5,441,868
|Title:||Production of recombinant erythropoietin|
|Abstract:||Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin (\"EPO\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Illustratively, genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequence of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Upon isolation from culture media or cellular lysates or fragments, products of expression of the DNA sequences display, e.g., the immunological properties and in vitro and in vivo biological activities of EPO of human or monkey species origins. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of EPO. Also disclosed are improved methods for the detection of specific single stranded polynucleotides in a heterologous cellular or viral sample prepared from, e.g., DNA present in a plasmid or viral-borne cDNA or genomic DNA \"library\".|
|Inventor(s):||Lin; Fu-Kuen (Thousand Oaks, CA)|
|Assignee:||Kirin-Amgen, Inc. (Thousand Oaks, CA)|
|Patent Claims:||1. A process for the production of a glycosylated erythropoietin polypeptide having the in vivo biological property of causing bone marrow cells to increase production of
reticulocytes and red blood cells comprising the steps of:
(a) growing, under suitable nutrient conditions, mammalian host cells transformed or transfected with an isolated DNA sequence encoding human erythropoietin; and
(b) isolating said glycosylated erythropoietin polypeptide therefrom.
2. The process according to claim 1 wherein said host cells are CHO cells.
3. The process according to claim 1 wherein said host cells are COS cells.
4. The process according to claim 1 wherein said DNA is cDNA.
5. The process according to claim 1 wherein said DNA is genomic DNA.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Amgen||EPOGEN/PROCRIT||epoetin alfa||VIAL; SINGLE-USE||103234||001||1989-06-01||⤷ Free Forever Trial||Kirin-Amgen, Inc. (Thousand Oaks, CA)||2012-08-15||RX||company|
|Amgen||EPOGEN/PROCRIT||epoetin alfa||VIAL; MULTIDOSE||103234||002||1989-06-01||⤷ Free Forever Trial||Kirin-Amgen, Inc. (Thousand Oaks, CA)||2012-08-15||RX||company|
|Amgen||EPOGEN/PROCRIT||epoetin alfa||VIAL; MULTIDOSE||103234||003||1989-06-01||⤷ Free Forever Trial||Kirin-Amgen, Inc. (Thousand Oaks, CA)||2012-08-15||RX||company|
|Amgen||EPOGEN/PROCRIT||epoetin alfa||VIAL; SINGLE-USE||103234||004||1989-06-01||⤷ Free Forever Trial||Kirin-Amgen, Inc. (Thousand Oaks, CA)||2012-08-15||RX||company|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|Austria||54940||⤷ Free Forever Trial|
|Australia||1007495||⤷ Free Forever Trial|
|Australia||2042192||⤷ Free Forever Trial|
|Australia||3612597||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.